4
Changes in Ownership
CRISPR Therapeutics AG Filed Acc 0001193125-26-104480
Chief Executive Officer sold 9,798 shares at $52.80 ($517,334)
- Chief Executive Officer acquired 19,250 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Kulkarni Samarth · Chief Executive Officer
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2026-03-10 | Exercise or conversion : show line 1 in the form | +19,250 | 245,356 | D | ||
| 2026-03-11 | Sale : show line 2 in the form | −9,798 | $52.80 | $517,334 | 235,558 | D |
| Open-market sales · 9,798 sh · avg $52.80 · $517,334 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2026-03-10 | Exercise or conversion : show line 3 in the form Restricted Stock Units | −19,250 | 19,250 | D |
Loading xslF345X05/ownership.xml…